Silexion Therapeutics (NASDAQ:SLXN) Releases Earnings Results, Beats Expectations By $204.70 EPS

Silexion Therapeutics (NASDAQ:SLXN) released its quarterly earnings data on Thursday. The company reported ($13.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($218.40) by $204.70, FiscalAI reports.

Silexion Therapeutics Trading Down 17.6%

NASDAQ SLXN traded down $0.57 on Thursday, reaching $2.66. The company’s stock had a trading volume of 70,729 shares, compared to its average volume of 135,559. The firm has a market cap of $617,120.00, a PE ratio of -0.06 and a beta of -0.30. The business has a 50-day moving average price of $5.83 and a 200 day moving average price of $142.68. Silexion Therapeutics has a 52 week low of $2.57 and a 52 week high of $777.12.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SLXN. Maxim Group lowered Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Silexion Therapeutics presently has a consensus rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.